First blood-stage malaria vaccine ‘a much-needed addition’ – analyst
The RH5.1/Matrix-M blood-stage vaccine could constitute a crucial secondary defence for communities at high risk of malaria infection, including those …
Post
-
-
Alumis reports positive outcomes from Phase I trial of TYK2 inhibitor
Alumis has revealed encouraging results from a Phase I clinical trial of a selective tyrosine kinase 2 (TYK2) inhibitor, A-005, …
-
Novo Nordisk takes a hit as CagriSema underperforms in weight loss
Danish mega-company Novo Nordisk has taken a hit after its newest experimental weight loss drug, CagriSema, fell short of expectations …
-
Adicet Bio doses first subject in Phase I trial of renal cell carcinoma therapy
US-based biotechnology company Adicet Bio has dosed the first subject in a multicentre Phase I trial of ADI-270, a gamma …
-
Sorriso Pharma’s UC treatment hits Phase Ib endpoints
Utah biopharma company Sorriso Pharmaceuticals has confirmed its Phase Ib trial of an oral drug for patients with ulcerative colitis …
-
MSD’s DOR/ISL regimen meets primary efficacy hypotheses in HIV-1 treatment trials
US-based pharmaceutical company MSD has reported positive results from two Phase III trials of doravirine/islatravir (DOR/ISL), an oral treatment regimen …
-
APAC leading in Parkinson’s disease clinical trials
The Asia-Pacific (APAC) region is leading in the Parkinson’s disease clinical trial space globally with 44% of trials, according to …
-
Vertex’s stock hurt after non-opioid pain drug shows benefit similar to placebo
Vertex Pharmaceuticals’s non-opioid-based pain therapy has shown benefit in a Phase II trial in patients with painful lumbosacral radiculopathy (LSR) …
-
Hansa Biopharma announces success in Guillain-Barré Syndrome trial
Swedish biotechnology firm Hansa Biopharma has announced that its investigational drug imlifidase improved motor function in patients with Guillain-Barré Syndrome …
-
New screening recommendations for critical congenital heart defects
In December 2024, the American Academy of Pediatrics published an updated screening algorithm for critical congenital heart defects (CCHD). According …
-
Sarepta completes subject dosing in Phase III LGMD2E/R4 therapy trial
Sarepta Therapeutics has completed enrolment and dosing in the global Phase III EMERGENE trial of its investigational gene therapy, SRP-9003 …
-
Prothena’s Parkinson’s study fails primary endpoint despite some success
Irish late-stage clinical biotechnology company, Prothena Corporation, has announced results from its Phase IIb study of prasinezumab failed to meet …
-
Remedy Plan commences dosing in Phase I cancer therapy trial
Remedy Plan Therapeutics has commenced dosing in a randomised Phase I trial of hyperbolic nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, RPT1G, for cancers. RPT1G …
-
Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial
Precision BioSciences has gained the approval of its clinical trial application (CTA) in Hong Kong to study PBGENE-HBV, a gene …
-
Immunocore doses first subject in gastrointestinal cancer therapy trial
Immunocore Holdings has dosed the first subject in a multicentre Phase I/II trial of IMC-R117C, a PIWIL1-targeted immunotherapy, for treating …
